Phaseline

Targets › SLC10A1

SLC10A1 (Hepatic sodium/bile acid cotransporter): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease.

As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins. It is strictly dependent on the extracellular presence of sodium. (UniProt, Q14973)

Open in Phaseline: the race on SLC10A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai HEP PharmaceuticalHepalatide (L47)
Bile acid transporter inhibitor
SLC10A1Phase 2Hepatitis D–

Conditions

Hepatitis D (1)

Modalities

protein or peptide (1)

Companies

Shanghai HEP Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.